Arvinas to Present at Upcoming Investor Conferences
04 mars 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update
28 avr. 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., April 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
16 mars 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 16, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...